MRS AND MRI OF BREAST CANCER AT VERY HIGH MAGNETIC FIELD

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目前没有临床成像方法提供足够的特异性来可靠地区分良性和恶性乳腺肿块。 病理学评估是目前获得明确诊断的唯一途径。 本研究的总体目标是开发和测试改进的高场（4特斯拉）MRS方法，并将其与对比增强（Gd-DTPA）MRI结合联合收割机用于乳腺癌的研究。 虽然MRS对于分析癌细胞的代谢状态具有很大的希望，但尚未确定体内某些代谢物的MRS检测是否可以为区分良性和恶性病变提供高诊断特异性。 我们认为，通过实施新的方法，利用高磁场，优化灵敏度，并从重叠的大分子共振（脂质），假阳性和假阴性诊断某些代谢物共振（胆碱化合物和13 C标记的乳酸盐），可以显着提高使用体内MRS识别恶性病变的能力，可以避免。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. No clinical imaging method currently provides sufficient specificity to reliably differentiate between benign and malignant breast lumps. Pathologic evaluation is the only way currently to obtain a definitive diagnosis. The general goal of this research is to develop and test improved high field (4 Tesla) MRS methods, and to combine them with contrast-enhanced (Gd-DTPA) MRI, in studies of breast cancer. While MRS holds great promise for profiling the metabolic status of cancer cells, it has not yet been determined whether MRS detection of certain metabolites in vivo can provide high diagnostic specificity for differentiating between benign and malignant lesions. We believe that the ability to identify malignant lesions can be significantly improved using in vivo MRS. By implementing new methods that exploit the high magnetic field, optimize sensitivity, and separate certain metabolite resonances (choline compounds and 13C labeled lactate) from overlapping macromolecular resonances (lipids), false-positive and false-negative diagnoses can be avoided.